<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ANDROGENS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>ANDROGENS</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid&#8212;causes masculinisation of female fetus.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid if possible&#8212;fluid retention and dose-related toxicity.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Caution&#8212;potential for fluid retention.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Breast cancer in males</li>
            <li>history of liver tumours</li>
            <li>hypercalcaemia</li>
            <li>prostate cancer</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Acne, androgenic effects (to be assessed regularly in women), anxiety, arthralgia, asthenia, changes in libido, cholestatic jaundice, depression, electrolyte disturbances, excessive duration of penile erection, excessive frequency of penile erection, gastro-intestinal bleeding, gynaecomastia, headache, hirsutism, hypercalcaemia, hypertension, increased bone growth, irritability, male-pattern baldness, muscle cramps, nausea, nervousness, oedema, paraesthesia, polycythaemia, precocious sexual development in pre-pubertal males, premature closure of epiphyses in pre-pubertal males, prostate abnormalities, prostate cancer, pruritus, seborrhoea, sodium retention, suppression of virilism in women, vomiting, weight gain,
              </p>
              <p>
                <strong>rare:</strong> Liver tumours,
              </p>
              <p>
                <strong>notKnown:</strong> Sleep apnoea,
              </p>
        
        
            <section class="advice">
                <h3>Polycythaemia</h3>
              <p>Stop treatment or reduce dose if severe polycythaemia occurs.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Androgenic effects in women</h3>
              <p>Women should be advised to report any signs of virilisation e.g. deepening of the voice or hirsutism.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac impairment
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            elderly
          </li>
          <li>
            epilepsy
          </li>
          <li>
            hypertension
          </li>
          <li>
            ischaemic heart disease
          </li>
          <li>
            migraine
          </li>
          <li>
            pre-pubertal boys (fusion of epiphyses is hastened and may result in short stature)&#8212;statural growth and sexual development should be monitored
          </li>
          <li>
            skeletal metastases&#8212;risk of hypercalcaemia or hypercalciuria (if this occurs, treat appropriately and restart treatment once normal serum calcium concentration restored)
          </li>
          <li>
            sleep apnoea
          </li>
          <li>
            stop treatment or reduce dose if severe polycythaemia occurs
          </li>
          <li>
            tumours&#8212;risk of hypercalcaemia or hypercalciuria (if this occurs, treat appropriately and restart treatment once normal serum calcium concentration restored)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor prostate and PSA in men over 45 years.</p>
            </section>
            <section class="patientParameters">
              <p>Monitor haematocrit and haemoglobulin before treatment , every three months for the first year, and yearly thereafter.</p>
            </section>
      </section>











      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of ANDROGENS</h2>

          <ul>
            <li><a href="../drug/PHP100921.html">TESTOSTERONE</a></li>
            <li><a href="../drug/PHP100922.html">TESTOSTERONE ENANTATE</a></li>
            <li><a href="../drug/PHP100923.html">TESTOSTERONE PROPIONATE</a></li>
            <li><a href="../drug/PHP100924.html">TESTOSTERONE UNDECANOATE</a></li>
            <li><a href="../drug/PHP106634.html">TESTOSTERONE DECANOATE, ISOCAPROATE, PHENYLPROPIONATE AND PROPIONATE</a></li>
            <li><a href="../drug/PHP4537.html">MESTEROLONE</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
